Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) is doing something rare in aerospace. It is building a fully vertically integrated space platform while still burning cash. Q1 revenue hit $200.35 million, up 63.5% year over year, backlog reached $2.20 billion, and management just announced an $8 billion acquisition of Iridium Communications.
Shares are up 33.44% year to date to $93.09. Can this stock hit $175 in 2027 and truly become the next SpaceX-caliber story? Let’s do the math.
Why Rocket Lab Shares Have Sold Off From May’s Peak
The near-term picture is ugly. RKLB is down 5.02% over the past week and 15.43% over the past month, well off its May peak.
Three things are weighing on the stock. A $3 billion at-the-market equity offering announced June 24 raised dilution fears. A securities class action was filed July 1 over Neutron timeline disclosures.
And SpaceX’s June 12 IPO triggered capital rotation out of smaller space names. With a beta of 2.553, RKLB amplifies every swing in sentiment. Right now that volatility is working against holders.
Wall Street Sees 22% Upside. I See Room for More.
Consensus target price sits at $114.10, with 3 strong buys, 11 buys, 4 holds, and zero sells. Bullish sentiment stands at 78%. Our base case lands at $124.25, implying 33.48% upside, with an optimistic scenario of $156.80 and a bear case at $97.12. Confidence is moderate.
I think the sell-side is behind the curve. Most targets were struck before the Iridium deal, and Roth Capital has already raised to $130. If Neutron flies in Q4 and Golden Dome contracts start converting, the consensus will follow.
The Path to $175 Per Share
Reaching $175 from today’s $93.09 requires a gain of 88%. With forward EPS at -$0.34, a $175 price implies a forward P/E of -515x, a meaningless figure because Rocket Lab remains unprofitable.
The valuation case rests on revenue and backlog conversion. Shares currently trade at roughly 92x sales against 63.5% quarterly revenue growth.
To justify $175, revenue needs to keep compounding through Neutron’s Q4 debut and the Iridium close in mid-2027. Catalysts are lining up: the $816 million SDA Tranche 3 contract, Golden Dome selection with Raytheon, and NASA’s PolSIR and TSIS-2 mission awards.
CEO Peter Beck framed it plainly on the Q1 call: “Rocket Lab’s tailwinds are strong. We’re already embedded in the most demanding and significant space programs of our generation.” The primary risk remains a further Neutron slip past Q4 2026.
Where Rocket Lab Trades Today vs Its Earnings Power
At $93.09, shares sit 24% below the 52-week high of $151 and well above the $37.57 low. Over five years, RKLB has returned 704.58%, and one-year returns come in at 161.05%.
Forward P/E is not usable with negative EPS, so investors are effectively paying 92x sales for a business the market expects to look nothing like a small-launch shop by 2028. That is the wager.
Is $175 Realistic? My Verdict
Reaching $175 requires an 88% gain, aggressive but plausible for a stock with beta above 2.5 and a five-year return already north of 700%. Three things have to break right.
Neutron needs a clean Q4 2026 debut. The Iridium deal has to close on time with credible integration. And backlog conversion must sustain something close to Q1’s 63.5% growth clip. A material Neutron delay would gut the thesis quickly. Returns at this level shouldn’t be expected every year, but we’ve outlined the blueprint for how Rocket Lab could reach $175 in 2027.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks